 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Omnicare (OCR) operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States and Canada. It provides pharmaceuticals, and related pharmacy and ancillary services to long-term care facilities, as well as chronic care facilities and other settings. The company operates institutional pharmacy business serving skilled nursing facilities, assisted living facilities, independent living communities, hospitals, correctional facilities, and other healthcare service providers; and offers pharmacy consulting services, including monthly patient drug therapy evaluations, assistance in compliance with state and federal regulations, and provision of proprietary clinical and health management programs. It also provides a suite of technology solutions based on its Omniview Web-based platform as the electronic ordering of prescription refills, proof-of-delivery tracking, and real-time validation of Medicare Part D coverage; intravenous medications and nutrition products, respiratory therapy services, medical supplies and equipment, and clinical care planning services; and pharmaceutical case management services for retirees, employees, and dependents. In addition, the company offers commercialization services for the biopharmaceutical industry; and end-of-life pharmaceutical care management for hospice care agencies. Its services include brand support services, third party logistics, patient assistance programs, specialty pharmacy, and disease management for end-of-life care. We are now hearing rumors of good news for this stock. One of the rumors states that when the firm report earnings on August 15th, the results will be much better than the Street expects. Shares are heading higher in a bullish "double bottom" and are expected to move higher in this formation. The stock has a 52-week trading range of $20.36 - $36.48. Shares last traded at $31.41. Should you decide to take a position, wait for the morning volatility to wear off and use a stop-loss of $29.82 (five percentage points below your purchase price.) Be sure to use a limit order and not a market order. Keep in mind that our price target is 10% higher than your purchase price.
